Skip to main content
SpringerLink
Log in

Pamiparib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Pamiparib (PARTRUVIX™; BeiGene Ltd.) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor being developed for the treatment of various cancers. Based on the results from the pivotal phase II portion of a phase I/II trial (NCT03333915) pamiparib was recently approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy. This article summarizes the milestones in the development of pamiparib leading to this first approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wu Z, Cui P, Tao H, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021. https://doi.org/10.1177/1179554921996288.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Businesswire. China NMPA approves PARP inhibitor pamiparib for patients with previously treated advanced ovarian cancer [media release]. May 7 2021. https://www.businesswire.com.

  3. BeiGene. Pamiparib: prescribing information. 2021.

  4. Xiong Y, Guo Y, Liu Y, et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020;22(9):431–40.

    Article  CAS  Google Scholar 

  5. Wang H, Ren B, Liu Y, et al. Discovery of pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development. J Med Chem. 2020;63(24):15541–63.

    Article  CAS  Google Scholar 

  6. Mu S, Palmer D, Fitzgerald R, et al. Human mass balance and metabolite profiling of [14C]-pamiparib, a poly (ADP-ribose) polymerase inhibitor, in patients with advanced cancer. Clin Pharmacol Drug Dev. 2021. https://doi.org/10.1002/cpdd.943.

    Article  PubMed  Google Scholar 

  7. Mu S, Lin C, Skrzypczyk-Ostaszewicz A, et al. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study. Cancer Chemother Pharmacol. 2021. https://doi.org/10.1007/s00280-021-04253-x.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wu X, Zhu J, Wang J, et al. Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC) [abstract no. 820P and Poster]. Ann Oncol. 2020;31 (Suppl 4):S619–20.

  9. Xu B, Yin Y, Dong M, et al. Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer. Cancer Med. 2021;10(1):109–18.

    Article  CAS  Google Scholar 

  10. Voskoboynik M, Mileshkin L, Gan H, et al. Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: updated phase I dose-escalation/expansion results [abstract no. 452PD]. Ann Oncol. 2019;30(Suppl 5):v167.

  11. BeiGene. BeiGene announces preliminary clinical data on PARP inhibitor pamiparib presented at annual scientific meeting and education day of the Society for Neuro-Oncology [media release]. 16 Nov 2018. http://www.beigene.com.

  12. Friedlander M, Meniawy T, Markman B, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(9):1306–15.

    Article  CAS  Google Scholar 

  13. Stradella A, Johnson M, Goel S, et al. Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ) [abstract no. 530MO]. Ann Oncol. 2020;31(Suppl 4):S465–6.

  14. Myriad Genetics. Myriad Genetics and BeiGene sign agreement to develop companion diagnostics for use with BeiGene’s novel PARP Inhibitor, BGB-290 [media release]. 06 Apr 2017. https://myriad.com.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Anthony Markham

Authors
  1. Anthony Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony Markham.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markham, A. Pamiparib: First Approval. Drugs 81, 1343–1348 (2021). https://doi.org/10.1007/s40265-021-01552-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01552-8

Search

Navigation